Series A companies: the class of 2023
An analysis of the technologies behind last year’s biotech series A raisers finds clusters in mitophagy induction, epigenome editing and delivery vectors
The bar was high for attracting series A investments in 2023, but at least 148 biotechs made the grade, collectively raising over $6.2 billion.
The 2023 crop of series A raisers brings fresh money to clusters of emerging technologies such as mitophagy inducers, epigenome editors and new delivery vectors. And with only the best getting funded last year, these companies may be particularly instructive for what innovations are coming down the pike...